Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction
Renal dysfunction, which comprises 10%-40% of acute heart failure patients (AHF), plays an important role in diuretic resistance mechanism. DR-AHF was designed to demonstrate the effectiveness of early tolvaptan (a vasopressin-2 receptor antagonist) add-on therapy in acute heart failure patients with renal dysfunction and clinical evidence of loop diuretic resistance.
100 项与 Otsuka Pharmaceutical Vietnam Joint Stock Company 相关的临床结果
0 项与 Otsuka Pharmaceutical Vietnam Joint Stock Company 相关的专利（医药）
100 项与 Otsuka Pharmaceutical Vietnam Joint Stock Company 相关的药物交易
100 项与 Otsuka Pharmaceutical Vietnam Joint Stock Company 相关的转化医学
